Sagimet Biosciences Inc.
Stories
-
Sagimet registers Phase 3 trial of denifanstat in moderate to severe acne vulgaris
The study, first posted on ClinicalTrials.gov on October 7, 2026, plans to enroll 800 participants and begin in October 2026. After a 12-week treatment phase, about 530 participants may consent to a 40-week open-label extension.